
Vanda Pharmaceuticals Unveils Imsidolimab Data at EADV Meeting
Vanda Pharmaceuticals is presenting new clinical data on imsidolimab at the European Academy of Dermatology and Venereology Annual Meeting in Vienna. The findings, showcased through three distinct presentations, highlight the drug's efficacy in treating Generalized Pustular Psoriasis and its specific impact on inflammatory markers.





















